Psychedelic News and Analysis Made Simple for Investors
Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.
Track the entire psychedelic market
We’ve developed the first all encompassing index to track the public psychedelic marketplace.
Explore the Index
Just Some of the Data we Cover
Latest News
Press
Oct 31
•
3 min read
Toronto, Ontario–(Newsfile Corp. – October 31, 2024) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is announcing it has successfully completed its stability study of its patented enteric-coated…
Press
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc. (“Psyence Group“) (CSE: PSYG) today announced the successful closing of its previously announced disposal of its 11.13% stake in privately held PsyLabs to its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (“PBM” or “Psyence Biomed“) (“Disposal“). Per the terms of the Disposal, Psyence Biomed…
Oct 31
•
4 min read
Press
10/31/2024 – 07:30 AM TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential…
Oct 31
•
3 min read
Press
SARASOTA, FL, Oct. 31, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced promising results from recent sterilization and dissolution tests of its SP-26 ketamine-loaded implant for fibromyalgia and…
Oct 31
•
3 min read
Press
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the successful closing of its previously announced acquisition of Psyence Group’s 11.13% stake in privately held PsyLabs. PsyLabs is focused on the cultivation and production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical trials and…
Oct 31
•
4 min read
Press
Vancouver, British Columbia –TheNewswire –29 October, 2024–MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6),(the “Company” or “MindBio”),is a leading clinical stage biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines to treat depressive disorders. The Company is delighted to report a significant and sustained antidepressant response in patient follow up 6 months post an 8-week treatment…
Oct 31
•
4 min read
Press
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 2024 Milken Institute Future of Health Summit on a panel entitled “The Next…
Oct 31
•
3 min read
Explore the Psychedelic Landscape
Learn more about the psychedelic companies changing the industry.